Form 8-K INTERCEPT PHARMACEUTICAL For: Mar 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
H.C. Wainwright Upgrades Intercept Pharmaceuticals (ICPT) to Neutral
March 12, 2021 6:15 AM UTCH.C. Wainwright analyst Ed Arce upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Sell to Neutral with a price target of $21.00 (from $25.00).
The analyst comments "We downgraded ICPT to Sell on February 23 when it traded at about $30 per share (prior close $29.86). The shares hit a multi-year low of $19.33 on March 4, and are now close to $21, largely on recent macroeconomic optimism, in our view. Our underlying thesis (NASH program has little to no risk-adjusted value, and PBC franchise faces substantial risks) has not changed. However, given the drop in... More
